Ginsenoside Rh2 substantially inhibits breast cancer growth and metastasis by enhancing NK cell cytotoxicity through direct binding to ERp5, thus modulating the NKG2D/MICA signaling axis, and holds potential as a therapeutic agent for breast cancer 205. Here, MICA is linked to breast carcinoma.